EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.
- DOI
- 10.1007/s13555-026-01883-y
- Published
- 2026 Aug 21
- Container
- Dermatology and therapy
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s13555-026-01883-y,
title = {EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.},
author = {Dehn S and Cooper D and Weyer C and Ferguson B and Srinivasan S and Saint-Cyr Proulx E and Bissonnette R},
year = {2026},
journal = {Dermatology and therapy},
doi = {10.1007/s13555-026-01883-y},
url = {https://doi.org/10.1007/s13555-026-01883-y}
}RIS
TY - JOUR TI - EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study. AU - Dehn S AU - Cooper D AU - Weyer C AU - Ferguson B AU - Srinivasan S AU - Saint-Cyr Proulx E AU - Bissonnette R PY - 2026 JO - Dermatology and therapy DO - 10.1007/s13555-026-01883-y UR - https://doi.org/10.1007/s13555-026-01883-y ER -
APA
S, D., D, C., C, W., B, F., S, S., E, S. P., & R, B. (2026). EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.. Dermatology and therapy. https://doi.org/10.1007/s13555-026-01883-y
Source records
- pubmed · retrieved 2026-09-26T00:36:38.315Z
- europe-pmc · retrieved 2026-09-26T00:36:38.333Z